Triazolo and tetrazolo pyrimidine derivatives as HNE inhibitors for treating COPD

US9359362B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Franz Von Nussbaum · Mülheim an der Ruhr, DE
• Dagmar Karthaus · Solingen, DE
• Sonja Anlauf · Wuppertal, DE
• Martina Delbeck · Essen, DE
• Volkhart Min-Jian Li · Velbert, DE
• Daniel Meibom · Leverkusen, DE
• Klemens Lustig · Wuppertal, DE

Key dates

• Filing date: Oct 7, 2013
• Grant date: Jun 7, 2016
• Expiry date: Oct 7, 2033

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/14
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to novel heterocyclically fused diaryldihydropyrimidine derivatives, to processes for their preparation, to their use alone or in combination for the treatment and/or prevention of diseases and also to their use for preparing medicaments for the treatment and/or prevention of diseases, in particular for the treatment and/or prevention of disorders of the lung and the cardiovascular system.